{"id":"https://openalex.org/W4297957608","doi":null,"title":"Deferiprone: new preparation. Poorly assessed.","display_name":"Deferiprone: new preparation. Poorly assessed.","publication_year":2000,"publication_date":"2000-10-01","ids":{"openalex":"https://openalex.org/W4297957608","pmid":"https://pubmed.ncbi.nlm.nih.gov/11603411"},"language":"en","primary_location":{"id":"pmid:11603411","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11603411","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Prescrire international","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.224,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.57336562,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"9","issue":"49","first_page":"131","last_page":"5"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.9628999829292297,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.9628999829292297,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10452","display_name":"Iron Metabolism and Disorders","score":0.03180000185966492,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/deferiprone","display_name":"deferiprone","score":1.0},{"id":"https://openalex.org/keywords/iron-chelation","display_name":"iron chelation","score":0.8100000023841858},{"id":"https://openalex.org/keywords/beta-thalassemia","display_name":"beta-thalassemia","score":0.9369999766349792},{"id":"https://openalex.org/keywords/iron-overload","display_name":"iron overload","score":0.9010000228881836},{"id":"https://openalex.org/keywords/deferoxamine","display_name":"deferoxamine","score":0.8889999985694885},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.7039999961853027},{"id":"https://openalex.org/keywords/liver-fibrosis","display_name":"liver fibrosis","score":0.921999990940094},{"id":"https://openalex.org/keywords/agranulocytosis","display_name":"agranulocytosis","score":0.9890000224113464},{"id":"https://openalex.org/keywords/teratogenicity","display_name":"teratogenicity","score":0.984000027179718},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.41600000858306885},{"id":"https://openalex.org/keywords/clinical-trial-evidence","display_name":"clinical trial evidence","score":0.3580000102519989},{"id":"https://openalex.org/keywords/regulatory-assessment","display_name":"regulatory evaluation","score":0.4090000092983246}],"concepts":[{"id":"https://openalex.org/C2776517179","wikidata":"https://www.wikidata.org/wiki/Q749664","display_name":"Deferiprone","level":3,"score":0.9915837049484253},{"id":"https://openalex.org/C2776672577","wikidata":"https://www.wikidata.org/wiki/Q419618","display_name":"Deferoxamine","level":2,"score":0.8399683237075806},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7507803440093994},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5754673480987549},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.498305082321167},{"id":"https://openalex.org/C2777218474","wikidata":"https://www.wikidata.org/wiki/Q1069061","display_name":"Chelation therapy","level":3,"score":0.46248680353164673},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40486037731170654},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4029366672039032},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33692610263824463},{"id":"https://openalex.org/C2777799968","wikidata":"https://www.wikidata.org/wiki/Q185137","display_name":"Thalassemia","level":2,"score":0.3047563135623932}],"mesh":[{"descriptor_ui":"D000380","descriptor_name":"Agranulocytosis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D002170","descriptor_name":"Canada","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005060","descriptor_name":"Europe","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007502","descriptor_name":"Iron Chelating Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007502","descriptor_name":"Iron Chelating Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017086","descriptor_name":"beta-Thalassemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019190","descriptor_name":"Iron Overload","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:11603411","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11603411","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Prescrire international","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2087887501","https://openalex.org/W2088067306","https://openalex.org/W32000358","https://openalex.org/W2334308892","https://openalex.org/W2046791562","https://openalex.org/W2312723416","https://openalex.org/W1995255139","https://openalex.org/W2140524632","https://openalex.org/W2007019338","https://openalex.org/W3131267202"],"abstract_inverted_index":{"Deferiprone,":[0],"an":[1,133],"oral":[2],"iron":[3,14,86],"chelator,":[4],"has":[5],"been":[6],"licensed":[7],"in":[8,16,80,111,132,142],"Europe":[9],"for":[10],"the":[11,32,46,106,120],"treatment":[12],"of":[13,28,56,70,108,130,136],"overload":[15],"patients":[17],"with":[18,25],"beta":[19],"thalassaemia":[20],"who":[21],"cannot":[22],"be":[23],"treated":[24],"deferoxamine":[26,79],"because":[27],"adverse":[29],"effects":[30],"or":[31,58],"difficult":[33],"administration":[34],"schedule.":[35],"(2)":[36],"The":[37,61],"clinical":[38],"dossier":[39,49],"is":[40,50,75,116,140],"thin":[41],"and":[42,84],"methodologically":[43],"mediocre.":[44],"Even":[45],"preclinical":[47],"assessment":[48],"insufficient":[51],"(there":[52],"are":[53],"no":[54],"studies":[55],"carcinogenicity":[57],"hepatotoxicity).":[59],"(3)":[60],"only":[62,100],"available":[63,122],"comparative":[64,91],"trial,":[65],"involving":[66],"a":[67,128],"small":[68],"number":[69],"patients,":[71],"suggests":[72,93],"that":[73,94],"deferiprone":[74,96],"less":[76],"effective":[77],"than":[78],"reducing":[81],"ferritin":[82],"levels":[83],"hepatic":[85],"stores.":[87],"(4)":[88],"A":[89],"non":[90],"trial":[92],"long-term":[95],"therapy":[97],"would":[98,103],"not":[99,117],"fail,":[101],"but":[102],"also":[104],"increase":[105],"risk":[107,129],"liver":[109],"fibrosis":[110],"some":[112],"patients.":[113,137],"This":[114],"doubt":[115],"dispelled":[118],"by":[119],"other":[121],"non-comparative":[123],"trials.":[124],"(5)":[125],"Deferiprone":[126,139],"carries":[127],"agranulocytosis":[131],"estimated":[134],"1.2%":[135],"(6)":[138],"teratogenic":[141],"two":[143],"animal":[144],"species.":[145]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-10-01T00:00:00"}